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Introduction: Low levels of vitamin D have been associated with several autoimmune disorders including
multiple sclerosis, rheumatoid arthritis, type 1 diabetes and systemic lupus erythematosus (SLE). The major source
of vitamin D is sunlight but exposure of SLE patients to UV rays has been shown to exacerbate disease pathology.
Studies in various populations have shown an association between low vitamin D levels and higher SLE disease
activity.
Methods: We enrolled 129 patients who fulfilled American College of Rheumatology criteria in the study. There
were 79 treatment-naïve cases and 50 patients who were under treatment for underlying SLE. There were 100
healthy subjects from similar geographical areas included as controls. Plasma 25-OH vitamin D3 and interferon
(IFN)-α levels were quantified by enzyme-linked immunosorbent assay (ELISA). The gene expression level of IFN-α
was determined by quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR).
Results: Plasma 25-OH vitamin D3 significantly correlated in an inverse manner with systemic lupus erythematosus
disease activity index (SLEDAI) scores (P <0.0001, r = −0.42), anti-dsDNA (P <0.0001, r = −0.39), plasma IFN-α
(P <0.0001, r = −0.43) and levels of IFN-α gene expression (P = 0.0009, r = −0.45). Further, plasma levels of IFN-α
positively correlated with gene expression of IFN-α (P <0.0001, r = 0.84). Treatment-naïve SLE patients displayed
significantly higher plasma levels of IFN-α compared to patients under treatment (P <0.001) and controls (P <0.001).
Conclusions: These results suggest an important role of vitamin D in regulating disease activity in SLE patients and the
need to supplement vitamin D in their treatment.Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disorder which appears in a group of individuals and
which is related to several factors, including environ-
mental and host genetics that contribute to the develop-
ment of the disease [1]. Patients with SLE develop an
immune response against numerous, mostly intracellular
self-antigens. This results in formation of immune com-
plexes that get deposited in vascular beds in most organs* Correspondence: ravindran8@gmail.com; bidyutdas@hotmail.com
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reproduction in any medium, provided the orof the body. Immune complex deposition causes local
inflammation and tissue damage that probably amplify
the autoimmune response [2]. This has serious conse-
quences on the outcome of the disease.
The importance of vitamin D in various autoimmune
disorders has been reported. Vitamin D deficiency has
been associated with multiple sclerosis (MS), rheumatoid
arthritis (RA), type 1 diabetes mellitus, inflammatory
bowel disease (IBD), mixed connective tissue disease,
autoimmune thyroid disease, scleroderma and SLE [3-5].
Vitamin D supplementation improves disease outcome
in various animal models of MS [6], RA [7], type 1 dia-
betes mellitus [8], IBD [9], autoimmune encephalomyeli-
tis [10] and SLE [11]. The role of vitamin D in murine
models of SLE has been investigated to a limited degree.
Administration of vitamin D and its synthetic analogs toLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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manifestations [11], reduced proteinuria [12] and in-
creased survival [12,13]. An earlier report highlighted
vitamin D3 insufficiency in two-thirds, and deficiency
(<10 ng/ml) in approximately one-fifth of SLE patients
[14]. In addition, serum vitamin D3 (25-OH) levels have
been found to correlate inversely with SLE disease activ-
ity index (SLEDAI) scores [15-17].
The major source of vitamin D is the conversion of 7-
dehydrocholesterol to previtamin D3 in the skin when
exposed to solar ultraviolet radiation [18]. Previtamin
D3 then gets converted to vitamin D3 (cholecalciferol)
through a heat-mediated process in the skin [18]. A
lesser amount of vitamin D3 (25-OH) is obtained from
foods that supply less than 20% of the body’s require-
ments. Vitamin D3 undergoes two hydroxylations to
achieve its functional form. The first hydroxylation occurs
in the liver resulting in 25-hydroxyvitamin D
(25(OH)D3) or calcidiol, which is normally quantified for
evaluating vitamin D status, and the second hydroxylation
takes place in the kidney to its active form 1,25-dihydroxy-
vitamin D3 (1, 25(OH)2D) [18]. In addition to the liver
and kidney, hydroxylation of vitamin D3 also occurs in the
lymph nodes and skin [19].
Several studies worldwide have investigated the role of
vitamin D3 in the pathogenesis of SLE. However, to date,
there have been no reports from an Indian population.
Although the prevalence of SLE in India is rare (3 per
100,000) [20], the survival rates of these patients (5-year:
70%; 10-year: 50%) are low compared to Western co-
horts [21,22]. Interestingly, vitamin D3 insufficiency or
deficiency appears to be widespread in the Indian sub-
continent [23], which makes it important to analyze its
role in the background of SLE from an Indian cohort.
We have addressed this issue in a tertiary-care, hospital-
based, case-control study, to assess the role of vitamin
D3 in SLE in a cohort from eastern India.
Methods
Subjects
The patients recruited for the study were all inpatients,
admitted to the Department of Medicine, under the Clin-
ical Immunology and Rheumatology unit of SCB Medical
College, Cuttack, Odisha. As described earlier [24-26],
diagnosis of SLE was based on the revised American Col-
lege of Rheumatology (ACR) classification criteria [27].
After a detailed clinical examination and laboratory inves-
tigation, the clinical manifestations were categorized. The
clinical profiles of 129 SLE patients are summarized in
Table 1. Since, SLE affects women primarily [28], 50 age-
matched healthy females (medical students: HCA) and 50
healthy subjects from similar geographical areas (HCB)
were included as healthy controls (HC). None of the con-
trols reported any history of autoimmune disorder. About5 ml blood in EDTA was collected from each participant.
The study was approved by the institutional ethics com-
mittee of SCB Medical College, Cuttack. Informed consent
was obtained from each patient and healthy control.
25-OH vitamin D quantification in plasma
The plasma levels of 25-OH Vitamin D were quantified by
enzyme-linked immunosorbent assay (ELISA) kit (CPC,
Euroimmun, Lübeck, Germany) according to the manufac-
turer’s instructions. Vitamin D deficiency was defined as
plasma levels of 25-OH vitamin D <10 ng/ml and insuffi-
ciency as 10 to 30 ng/ml [18].
Quantification of plasma interferon alpha
Plasma levels of interferon (IFN)-α were measured by
ELISA kit (Bender MedSystems Inc., Burlingame, CA,
USA) according to the manufacturer’s protocol.
RNA extraction and reverse transcription
According to the manufacturer’s instructions, total RNA
was isolated from 250 μl of whole blood by TRIzol LS
reagent (Invitrogen, Carlsbad, CA, USA). RNA concen-
tration was determined by spectrophotometry using an
Implen NanoPhotometer (Implen, Munich, Germany).
To remove any traces of genomic DNA, 1 μg of total
RNA was then treated with 2U DNase (Sigma-Aldrich,
St Louis, MO, USA) for 30 min at 37°C. DNase-treated
RNA was reverse transcribed with a hexamer primer
using a First Strand cDNA Synthesis kit (Thermo Fisher
Scientific, Waltham, MA, USA), according to the manu-
facturer’s instructions. Once the cDNA was synthesized,
its fidelity was tested by PCR and stored at −70°C.
Real-time PCR assay
Real-time PCR assay of IFN-α was carried out as des-
cribed earlier [29]. Briefly, reactions were set up in a total
volume of 20 μl using 2 μl of cDNA, 10 μl of MESA
GREEN qPCR MasterMix Plus (Eurogentec, Seraing,
Belgium) and 10 picomole each of gene-specific primer
(IFN-α (sense: 5′-TTCCTCCTGYYTGAWGGACAGA-3;
antisense: 5′-GATCTCATGATTTCTGCTCTGACA-3′),
glyceraldehyde-3 phosphate dehydrogenase (G3PDH) was
taken as control (sense: 5′-GGTATCGTGGAAGGACT
CATGAC-3′; antisense: 5′-ATGCCAGTGAGCTTCCC
GTTCAGC-3′)) and performed in the MJ Research DNA
Engine Opticon Real-Time Thermal Cycler (MJ Research,
Waltham, MA, USA).The cycling conditions were: 95°C for
4 min; 35 cycles of 95°C for 30 s, 55°C for 30 s and 72°C
for 30 s with a single fluorescence measurement; a final
elongation step was carried out at 72°C for 10 min. Specifi-
city of the PCR products was confirmed by analysis of the
dissociation curve. The melting curve program consisted of
temperatures between 55 and 95°C with a heating rate of
0.1°C/s and a continuous fluorescence measurement.
Table 1 Clinical characteristics of SLE patients and healthy controls
Clinical profiles SLE (n = 129) Healthy controls (n = 100)
Sex (male/female) 4/125 26/74
Age in years (mean ± SD) 28.14 ± 8.43 31.18 ± 5.32
Duration of disease years (mean ± SD) 2.90 ± 2.66 -
SLEDAI scores (mean ± SD) 18.36 ± 6.73 -
Photosensitivity rash 34 (26) -
Malar rash 73 (57) -
Discoid rash 14 (11) -
Oral ulcer 76 (59) -
Arthritis 77 (60) -
NPSLE 11 (9) -
Myocarditis 3 (2) -
Serositis 7 (5) -
Nephritis 46 (37) -
Vasculitis 17 (13) -
Treatment details of patients under therapy at the time of recruitment to the study
(n = 50)
Medicine Quantity Number of patient treated (%)
Prednisolone; mean (range) 18.99 mg (5-50 mg) 50 (100)
Hydroxychloroquine 6.5 mg/kg body weight 50 (100)
Calcium 1 g/day 50 (100)
Vitamin D3 250-500 IU/day 50 (100)
Azathioprine 50-100 mg/day 4 (8)
Mycophenolate mofetil 2 gm/day 4 (8)
Note: data are number (%) of participants unless otherwise specified. SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index; NPSLE,
neuropsychiatric systemic lupus erythematosus.
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of nonspecific products were confirmed by analysis of the
real-time PCR products in 1% agarose gel in 1 × TBE,
stained with ethidium bromide and visualized under ultra-
violet light (expected product size of IFN-α: 375 bp and
G3PDH: 187 bp). IFN-α gene expression in each sample
was calculated by the 2-ΔCt method (ΔCt =Ct of IFN-α –
Ct of GAPDH) [30].
Statistical analysis
All statistical analysis was performed by GraphPad prism
5.01 (GraphPad Software, San Diego, CA, USA). Dis-
tribution of plasma 25-OH vitamin D3 and IFN-α in
treatment-naïve SLE patients, controls and treated pa-
tients were assessed by D’Agostino-Pearson omnibus nor-
mality test. Based on the results of the normality test, the
association of 25-OH vitamin D3 and IFN-α with clinical
disease was analyzed by analysis of variance (ANOVA) or
Kruskal-Wallis test followed by an appropriate post test.
Correlation of 25-OH vitamin D3 with double-stranded
(ds)DNA, SLEDAI scores and IFN-α was analyzed by
Spearman’s correlation test. Further correlation of IFN-α
gene expression with plasma IFN-α and 25-OH vitaminD3 levels was analyzed by Spearman’s correlation test. A
P value <0.05 was considered as significant.
Results
Clinical characteristics of SLE patients
One hundred and twenty-nine patients were enrolled in
the current study. Baseline characteristics are shown in
Table 1. There were 125 (97%) females and 4 (3%) males
with a mean age (standard deviation) of 28.14 (8.43) years.
The mean duration of disease (standard deviation) was
2.90 years (2.66). Out of the 129 SLE patients, 50 patients
included in the study were already on treatment for SLE
and were also receiving supplements of oral calcium and
vitamin D3 at the time of blood collection (Table 1). The
other 79 patients were treatment-naive cases, undiagnosed
earlier and the details of the treatment received for their
complaints before hospitalization were not known since
the patients had not maintained any records. The clinical
profiles of patients were as follows: photosensitivity rash
(26%), malar rash (57%), discoid rash (11%), oral ulcer
(59%), arthritis (60%), neuropsychiatric disease (9%), myo-
carditis (2%), serositis (5%), nephritis (37%) and vasculitis
(13%) (Table 1).
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healthy controls
Plasma levels of 25-OH vitamin D3 in SLE patients and
healthy controls were quantified by ELISA and the results
are shown in Figure 1. Patients under vitamin D3 supple-
mentation (treated cases) displayed significantly higher
levels of 25-OH vitamin D3 compared to treatment-naïve
patients (P <0.001) and healthy controls (P <0.001). The
levels of plasma 25-OH vitamin D3 in treatment-naïve
SLE patients and healthy controls were comparable.Vitamin D3 levels negatively correlated with SLEDAI
scores and anti-dsDNA
Analysis of data in SLE patients revealed a significant nega-
tive correlation between plasma 25-OH vitamin D3 levels
with SLEDAI scores (P <0.0001, r = −0.42) (Figure 2A) and
anti-dsDNA (P <0.0001, r = −0.39) (Figure 2B). Further,
SLE patients were categorized into two groups: treatment-
naïve and those under treatment. As shown in Figure 2C
and D, irrespective of treatment status, the plasma levels of
25-OH vitamin D3 negatively correlated with SLEDAI
scores. In addition, a further analysis of the relationship be-
tween 25-OH vitamin D3 and modified SLEDAI scores
(eliminating the anti-dsDNA positive score of 2 from
SLEDAI), revealed identical results in both the groups
(Figures 2E and F). These findings indicate a significant as-
sociation between 25-OH vitamin D3 and disease activity
in SLE.Correlation between 25-OH vitamin D3 and IFN-α
The role of IFN-α in SLE has been clearly documented
and its significant correlation with SLEDAI scores hasFigure 1 25-OH vitamin D3 levels in SLE patients and healthy
controls. Plasma samples from SLE patients (treatment-naïve case
(n = 79); treated patients (n = 50)) and healthy controls (HCA:
medical students (n = 50); HCB: controls from same locality (n = 50))
were quantified by ELISA according to the manufacturer’s
instructions. Treated SLE patients displayed significantly higher
concentrations of plasma 25-OH vitamin D3 levels compared to
treatment-naïve patients (P <0.001) and controls (HCA: (P <0.001);
HCB: (P <0.01)). SLE, systemic lupus erythematosus.been demonstrated in patients from different populations
[31,32]. As shown in Figure 3A, a significant negative cor-
relation was observed between 25-OH vitamin D3 levels
and plasma IFN-α (P <0.0001, r = −0.43). Treatment-naïve
patients displayed higher levels of plasma IFN-α compared
to SLE patients on treatment (P <0.001) and healthy con-
trols (P <0.001) (Figure 3B) suggesting an important role
of IFN-α in modulating disease activity.
Correlation of IFN-α gene expression with plasma IFN-α
and 25-OH vitamin D3 levels
To validate the robustness of IFN-α data, considering
that it is an evanescent cytokine, we quantified IFN-α
gene expression by RT-PCR in SLE patients (n = 49) and
correlated the values with plasma levels of IFN-α and
25-OH vitamin D3. As shown in Figure 4A, a strong
positive correlation was observed between IFN-α plasma
levels and its gene expression (P <0.0001, r = 84). In
addition, IFN-α gene expression negatively correlated
with plasma 25-OH vitamin D3 (P = 0.0009, r = −45)
(Figure 4B).
Association of plasma IFN-α with SLE disease severity
Role of IFN-α in the pathogenesis of SLE is an important
issue that is being investigated [32]. We analyzed the as-
sociation of IFN-α with disease severity. As shown in
Figure 5A, plasma levels of IFN-α positively correlated
with SLEDAI scores (r = 0.26, P = 0.002) and patients
with severe phenotype displayed significantly higher
levels of IFN-α compared to those with mild disease
manifestations (P = 0.01) (Figure 5B). However, duration
of disease did not correlate with plasma IFN-α levels
(data not shown). We also observed a significant inverse
correlation between plasma 25-OH vitamin D3 and IFN-
α levels. This correlation held true while analyzing the
association between 25-OH vitamin D3 levels and IFN-α
gene expression.
Discussion
The role of vitamin D3 in autoimmune disorders has
been the subject of several studies with regard to its im-
portance as an immune regulator [33]. This is the first
study from India to demonstrate an association between
vitamin D3 and SLE, highlighting its significant inverse
correlation with SLEDAI scores, anti-dsDNA and IFN-α.
These are markers of disease activity and IFN-α is
closely associated with disease pathogenesis.
Low levels of vitamin D3 in SLE patients have been re-
ported compared to healthy controls in different popu-
lations [34]. Interestingly, mean plasma levels of 25-OH
vitamin D3 were not significantly different among treat-
ment-naïve SLE cases (11.61 ng/ml), healthy medical stu-
dents (9.55 ng/ml) and other healthy controls from same
locality (13.36 ng/ml). Vitamin D3 insufficiency has been
Figure 2 Correlation of 25-OH vitamin D3 with SLEDAI scores and anti-dsDNA levels. Plasma 25-OH vitamin D3 levels of SLE patients
correlated negatively with SLEDAI scores (A) and anti-dsDNA (B). SLE patients were categorized into two groups: treatment-naïve cases and
patients under treatment. In both groups plasma levels of 25-OH vitamin D3 negatively correlated with SLEDAI scores (C and D). Modified SLEDAI
scores (eliminating the anti-dsDNA score of 2) and its correlation with plasma levels of 25-OH vitamin D3 were analyzed. Similar to earlier observations,
SLEDAI scores (−anti-dsDNA) negatively correlated with 25-OH vitamin D3 levels in both treatment-naïve cases (E) and treated patients (F). Dots
represent individual samples. Correlation analysis was performed by Spearman’s correlation coefficient. A P value less than 0.05 was considered as
significant. SLEDAI, systemic lupus erythematosus disease activity index; SLE, systemic lupus erythematosus; dsDNA, double-stranded DNA.
Figure 3 Correlation of plasma IFN-α with 25-OH vitamin D3 and its levels in SLE patients and controls. (A) Plasma 25-OH vitamin D3
levels correlated negatively with IFN-α levels. Dots represent individual samples. Correlation analysis was performed by Spearman’s correlation
coefficient. (B) Treatment-naïve patients displayed significantly higher levels of IFN-α compared to treated cases and healthy controls. Mean
plasma levels of IFN-α in different clinical categories were compared by ANOVA followed by Tukey’s multiple comparisons test. A P value less than
0.05 was considered as significant. IFN-α, interferon alpha; SLE, systemic lupus erythematosus.
Mandal et al. Arthritis Research & Therapy 2014, 16:R49 Page 5 of 8
http://arthritis-research.com/content/16/1/R49
Figure 4 Correlation of IFN-α gene expression with plasma IFN-α levels and 25-OH vitamin D3. Plasma levels of IFN-α and gene expression
levels were quantified by ELISA and RT-PCR respectively. (A) Plasma levels of IFN-α positively correlated with gene expression (2 – Δct) of IFN-α.
(B) IFN-α gene expression (2 – Δct) correlated negatively with plasma levels of 25-OH vitamin D3. Dots represent individual samples. Correlation
analysis was performed by Spearman’s correlation coefficient. A P value less than 0.05 was considered as significant. IFN-α, interferon alpha.
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irrespective of the social class [23]. Two groups of healthy
controls were analyzed, which included medical students
(HCA), who led a lifestyle marked by poor exposure to
sunlight and irregular dietary habits, and a group of
healthy subjects from the same locality (HCB). Interest-
ingly, 63% of healthy medical students were deficient and
37% were insufficient of vitamin D3. Furthermore, 94% of
the other groups of healthy controls were either deficient
or insufficient of vitamin D3. This was an important obser-
vation considering India being a tropical country with lots
of sunshine. However, the facts were contrary and several
hypotheses have been discussed to explain the discrep-
ancy. Higher melanin concentration in the skin [35],
current lifestyle changes, avoidance of sunlight and poor
food habits are some of the causes attributed to the wide-
spread prevalence of low vitamin D3 among Indians. Low
vitamin D3 may not be cause for development of SLE butFigure 5 Correlation of plasma IFN-α with SLEDAI scores and associat
correlated with SLEDAI scores. Dots represent individual samples. Correlatio
P value less than 0.05 was considered as significant. (B) Based on clinical p
plasma levels of IFN-α were compared. Patients with major disease manifes
with minor disease manifestation. Mean plasma levels of IFN-α were comp
significant. IFN-α, interferon alpha; SLEDAI, systemic lupus erythematosus dpersons with low serum levels are likely to suffer from se-
vere disease. The current cross-sectional study does not
address the issue of cause and effect relationship between
vitamin D3 and SLE.
There are several interesting observations in the
current study that points to an important role for vita-
min D3 in disease modulation. One of them being a
significant inverse correlation between vitamin D3 and
SLEDAI scores and the other association is between
vitamin D3 and anti-dsDNA. Association between plas-
ma vitamin D3 and SLEDAI scores has not been uniform
across observations: several studies have reported a
negative correlation [15-17], while others have found
none [36-39].
One of the important functions of vitamin D3 is main-
tenance of homeostasis of B cells [40]. Low levels of
vitamin D3 contribute to hyperactivity of B cells and en-
hanced production of autoantibodies [41]. Furthermore,ion with organ involvement. (A) Plasma levels of IFN-α positively
n analysis was performed by Spearman’s correlation coefficient. A
henotype SLE patients were categorized into two broad groups and
tation displayed significantly higher plasma levels of IFN-α than those
ared by unpaired t test and a P value less than 0.05 was taken as
isease activity index; SLE, systemic lupus erythematosus.
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pathways [33] and thus could have a defining role in
the development, progression and pathogenesis of SLE.
Vitamin D3 also inhibits differentiation of dendritic cells
(DCs) and T-helper cells (CD4+) [42], enhances T regu-
latory cell proliferation and suppresses release of inflam-
matory mediators [43], which collectively help in control
of autoimmune disorders.
In recent years, the role of interferon in the pathoge-
nesis of lupus has been widely investigated. Higher levels
of IFN-α were observed in our SLE patients compared
to healthy controls, corroborating earlier observations
[32,44-46]. The interferon levels were significantly low
in patients under treatment compared to treatment-
naïve cases, supporting its possible role in disease modu-
lation. Furthermore, IFN-α could be a marker of disease
activity and low levels in treated patients could indicate
response to therapy.
Interestingly, our study revealed a strong negative cor-
relation of vitamin D3 with IFN-α (P <0.0001, r = −0.52).
The robustness of the assay was validated by assessment
of IFN-α gene expression, which corroborated with the
earlier observations on the association between plasma
IFN-α and vitamin D3. There are no reports in the
literature assessing the association between IFN-α and
vitamin D3.
In active SLE overexpression of interferon-inducible
genes (IFN signature) has been reported [47]. The major
source of IFN-α in SLE patients are activated DCs.
Maturation/activation of DCs and production of IFN-α
has been observed to be inhibited by vitamin D in in vitro
studies [48,49]. A direct role for vitamin D3 in modulating
lupus activity has been demonstrated in animal models
[11-13]. Our observations, although cross-sectional, and
studies on experimental models, provide evidence for a
disease-modulating role for vitamin D3, which could be a
promising therapeutic adjunct in the treatment of SLE. In
view of the limited number of drugs available for the treat-
ment of lupus and the low cost of vitamin D3 therapy,
there is a strong case for its use routinely.Conclusions
To conclude, vitamin D deficiency is prevalent among
healthy Indians as well as among SLE patients. The signifi-
cant inverse correlation of vitamin D3 with SLEDAI
scores, anti-dsDNA and IFN-α highlights its immune-
modulatory role contributing to disease outcome. Al-
though the present study indicates a necessity for vitamin
D3 supplementation in the management of SLE patients,
larger randomized controlled trials would be necessary to
define the daily requirement and optimum blood levels
of vitamin D3 that are effective in influencing disease
outcome.Abbreviations
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